

ALLIGATOR BIOSCIENCE TO PARTICIPATE IN UPCOMING SCIENTIFIC CONFERENCES IN SEPTEMBER 2022

Lund, Sweden, September 6, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following scientific conferences during September 2022:

- **ESMO Congress 2022, September 9 - 13, Paris**
Malin Carlsson, Executive Vice President & Chief Operating Officer at Alligator Bioscience, and Karin Nordbladh, Director of Clinical Operations at Alligator Bioscience, to attend in-person.
Registration for the conference is open [here](#).
- **AACR Special Conference on Pancreatic Cancer, September 13 - 16, Boston**
Yago Pico de Coaña, Medical Science Director at Alligator Bioscience, to present complete data from the Phase 1b dose escalation part of mitazalimab OPTIMIZE-1 Phase 1b/2 trial in first-line metastatic pancreatic cancer.
Registration for the conference is open [here](#).
- **13th World Bispecific Summit, September 20 - 22, Boston**
Laura von Schantz, Vice President of Discovery at Alligator Bioscience, to give a presentation entitled "*Kick-Starting Tumor Specific T Cell Cross-Priming Using Neo-X-Prime Bispecific Antibodies Targeting CD40*" at 01:45 pm EDT / 07:45 pm CEST on September 21.
Registration for the conference is open [here](#).
- **Immuno UK, September 29-30, London**
Peter Ellmark, Chief Scientific Officer at Alligator Bioscience, will give a presentation entitled "*Targeting the Myeloid Population In The Tumour Microenvironment*" at 01:45 pm BST / 2:45 pm CEST on September 30.
Registration for the conference is open [here](#).

PRESS RELEASE

06 September 2022 08:00:00 CEST



Contacts

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0)46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: gvanrenterghem@lifesciadvisors.com

Phone: +41 (0)76 735 01 31

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Alligator Bioscience to Participate in Upcoming Scientific Conferences in September 2022